Shots:
The P-III (TALAPRO-2) trial assessed Talzenna + Xtandi vs PBO + Xtandi in mCRPC ± HRRm pts for >4yr. (mFU: 52.5mos.) that were randomized into 2 Arms (A1: no genetic selection & A2: HRRm pts)
A1 showed reduced death risk by 20% & mOS of 45.8 vs 37mos. while A2 depicted death risk…
